Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
The phase III trial involved patients with very late stage lung cancer where the disease had spread to other organs - in other words, the group was hard to treat
RXC006 is a new breed of pill called a porcupine inhibitor
The company has partnered with Precision Biosciences of the US
The company is developing MED2005, a fast-acting gel for men who suffer erectile dysfunction
Arix is a cornerstone investor in the ASX life sciences group
The company has raised £850,000 before expenses, which will be used to develop potential treatments for cancer and autoimmune diseases
It is paying £4.4mln or 2.4-times revenues for Caledonian Holdings
The pioneer of the human microbiome, the bacteria that inhabit the gut and skin, will work with CTC which will distribute weight management product SlimBiome in the Philippines, Vietnam, Indonesia and Colombia
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.